BioSig Technologies (OTCQB:BSGM, OTCQB:BSGMD), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced that its shares of common stock have been approved for trading on the Nasdaq Capital Market, commencing on Friday, September 21. As quoted in the …

As quoted in the press release:

“We are extremely pleased to be stepping onto the Nasdaq Capital Market at this pivotal point,” stated Mr. Kenneth Londoner, Chairman and CEO of BioSig Technologies. “We begin trading on one of the world’s finest exchanges with a strong balance sheet, world-class IP, a leadership team with deep clinical and commercial expertise and support of several of the leading medical centers of excellence in our country. Our management and the Board of Directors believe that listing on the Nasdaq enables us to expand our shareholder base and provide access to a broader range of institutional investors worldwide as we commence targeted commercialization in the U.S., ultimately leading to the increase of shareholder value.”
The Company’s stock uplisting comes shortly after receiving the FDA 510(k) clearance for its first product, PURE EP(tm) System, the advanced signal acquisition and processing technology aimed to improve patient outcomes in the treatments of arrhythmia (irregular heartbeat). The Company completed 13 pre-clinical studies at Mayo Clinic and Mount Sinai to date and received first units from its contract manufacturer, Minnetronix earlier this month. BioSig recently made an announcement about strengthening its physician engagement efforts and continues to add experienced industry hires to its clinical and commercial teams.

Click here to read the full press release.

otcqb:bsgm Medical Device Investing